Zacks Research Cuts Earnings Estimates for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Investment analysts at Zacks Research cut their Q2 2027 earnings estimates for Avanos Medical in a research report issued on Wednesday, March 18th. Zacks Research analyst Team now expects that the company will earn $0.14 per share for the quarter, down from their prior forecast of $0.32. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s FY2027 earnings at $0.93 EPS.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Tuesday, February 24th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. The business had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The company’s revenue was up .7% compared to the same quarter last year. During the same period last year, the business posted $0.43 EPS. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS.

AVNS has been the subject of several other reports. Wall Street Zen downgraded Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

Avanos Medical Trading Down 3.0%

Shares of NYSE:AVNS opened at $13.05 on Monday. The company has a market cap of $607.00 million, a P/E ratio of -8.26 and a beta of 1.07. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.15 and a quick ratio of 1.26. Avanos Medical has a 1 year low of $9.30 and a 1 year high of $15.68. The stock’s fifty day moving average price is $13.66 and its 200-day moving average price is $12.32.

Institutional Trading of Avanos Medical

Large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. increased its position in Avanos Medical by 1,596,514.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company’s stock valued at $167,287,000 after acquiring an additional 14,895,480 shares during the last quarter. Armistice Capital LLC boosted its position in Avanos Medical by 28.0% in the fourth quarter. Armistice Capital LLC now owns 3,200,000 shares of the company’s stock worth $35,936,000 after purchasing an additional 700,000 shares during the last quarter. State Street Corp grew its stake in shares of Avanos Medical by 2.8% during the 4th quarter. State Street Corp now owns 1,954,785 shares of the company’s stock valued at $21,952,000 after purchasing an additional 53,523 shares during the period. Geode Capital Management LLC increased its position in shares of Avanos Medical by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,084,504 shares of the company’s stock valued at $12,180,000 after purchasing an additional 16,980 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Avanos Medical by 20.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,040,666 shares of the company’s stock valued at $11,687,000 after purchasing an additional 176,716 shares during the last quarter. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.